NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Arcutis's financial performance and business progress were discussed.
Arcutis Biotherapeutics reported total revenues of $5.2 million for Q2 2023, with ZORYVE contributing $4.8 million, a 72% increase from Q1 2023. The company's commercial coverage expanded to over 130 million commercial lives in the US, and ZORYVE was launched in Canada. Arcutis had approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023.
- Total revenues reached $5.2 million in Q2 2023.
- ZORYVE net product revenues were $4.8 million, a 72% increase compared to Q1 2023.
- Commercial payer coverage for ZORYVE expanded to over 130 million lives in the US.
- ZORYVE was launched in Canada in June 2023.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$5.19M
Forward guidance
Arcutis will continue to invest to fuel the next leg of the psoriasis launch, while also preparing for the upcoming launches in seborrheic dermatitis and atopic dermatitis in 2024, upon their respective anticipated U.S. Food and Drug Administration (FDA) approvals.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro